Company receives shareholder support to transition toward its nanotechnology and health sciences focus
Retains CORE IR for investor relations, public relations, U.S. listing advisory and capital markets advisory
Guelph, ON
October 4, 2021
ZEN Graphene Solutions Ltd. (“ZEN” or the “Company”) (TSX-V:ZEN and OTC:ZENYF), a Canadian, nanotechnology company focused on next-gen healthcare solutions, today announces that shareholders have approved all resolutions put forward at the annual shareholder meeting held on September 27, 2021. These resolutions include several initiatives to better align the company’s classifications and communications with its value proposition in nanotechnology and health sciences.
“We are extremely grateful and pleased that our shareholders are as enthusiastic about the new direction of our company as everyone here on the ZEN team. These resolutions will allow us to more properly position ZEN as an IP development company focused on technologies that enhance safety and improve health. We expect these steps to generate additional interest in the U.S. investment community and other markets where our story is currently underserved. These initiatives include potential listings on alternative exchanges in both the U.S. and Canada, a corporate name change, and a long-term incentive program for our employees aligned with these goals,” commented Greg Fenton, ZEN CEO.
The Company also recently retained CORE IR, a New York based investor and public relations firm focused on small to mid-cap companies, to assist in establishing relationships in the U.S. capital markets, advise on a potential US listing, interface with investors and engage in PR activities that provide greater visibility for the Company and its mission.
About Zentek Ltd.
Zentek is a graphene technology company focused on the research, development, and commercialization of graphene-based novel products to give our commercial partners a competitive advantage by making their products better, safer and greener.
Zentek’s patented ZenGUARD™ coating is shown to have 99% antimicrobial activity and significantly increase the bacterial and viral filtration efficiency for surgical masks and aims to do the same for HVAC filters. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario.
Our second technology platform is ZenARMOR™, which is patent-pending and focused on corrosion protection applications
To find out more about Zentek Ltd., please visit our website at www.zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR profile at www.sedar.com.
Forward-Looking Statements
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.